HYD
Hydrix Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Hydrix Ltd. engages in the development, design, and commercialization of technologies in the micro-electronic-mechanical systems (MEMS) sensor industry. The company is headquartered in Mulgrave, Victoria and currently employs 70 full-time employees. The company went IPO on 2001-05-11. The company is focused on the development of cardiovascular product technologies and venture investment in early stage MedTech clients. The firm's segments include Hydrix Services, Hydrix Medical and Hydrix Ventures. The Hydrix Services segment offers a range of engineering and regulatory services, including software, electronics, mechanical, industrial design, and general product development services. Its product development and commercialization services range from applied research through all stages of engineering design, development, prototyping, manufacturer management. The Hydrix Medical segment distributes cardiac monitoring and diagnostic medical device technologies, including the AngelMed Guardian and Phyzhon’s PHYRARI FFR-WIRE product. The Hydrix Ventures segment is engaged in investments in medical technologies.
📈 Performance
Price History
-35.56%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.03
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in HYD
1
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in HYD
767 days
HYD investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
100%
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in HYD also invest in...
VEU.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard All-World ex-US Shares Index ETF seeks to track the return of the FTSE All-World ex US Index before taking into account fees, expenses and tax
📊 Share price
$82.10 AUD
NULL GLOBAL
NULL OTHER
NULL EX US
NULL BETA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
📊 Share price
$120.79 AUD
NULL AUSTRALIA
NULL BETA
GEAR.AX was created on 2014-04-30 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 370.21m in AUM and 200 holdings. The Fund aims to provide investors with geared exposure to a diversified portfolio of Australian shares as simply as buying any share on the ASX. As the fund is internally geared, investors do not need to take out margin loans and do not have the possibility of margin calls in relation to their investment in the Fund.
📊 Share price
$24.70 AUD
NULL AUSTRALIA
NULL BETA
NULL GEARED
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
📊 Share price
$57.36 AUD
NULL GLOBAL
NULL SMART BETA
Want more shares? Try these...
Hexagon Energy Materials Ltd is a AU-based company operating in Metals & Mining industry. Hexagon Energy Materials Limited is an Australia-based company focused on future energy project development and future energy materials exploration and project development. The firm is focused on delivering decarbonized hydrogen to export and domestic markets. Its exploration projects include the McIntosh nickel-copper-platinum group elements (PGE) and graphite project, Halls Creek Gold and Base metals project, WAH2 Blue Hydrogen Project, and Ceylon project. The WAH2 Project is its flagship project to supply low-emissions blue ammonia to the decarbonizing powerhouse economies of the Asia Pacific, including Japan and South Korea. The McIntosh Project comprises approximately 17 exploration tenements spanning over 542 square kilometers (km2) in the East Kimberley region of Western Australia. The Halls Creek Project comprises over 13 granted tenements spanning 657 km2, located in the gold and base metals mining province of the East Kimberley region of Western Australia.
📊 Share price
$0.01 AUD
Hexima Ltd. is a biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-12-01. The firm is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The firm is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. The company is also investigating the application of its plant defensin technology to other human fungal diseases.
📊 Share price